Novartis AG has entered into an option agreement with Ionis Pharmaceuticals Inc. (formally Isis Pharmaceuticals) and its affiliate Akcea Therapeutics, Inc. to license two early-stage antisense treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
The two Ionis pipeline therapies included in the deal are AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx. The proposed deal includes a $75m upfront option payment as well as customary development, regulatory and commercial milestones and royalty payments to Ionis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?